However, overall, the general impression of the clinical investigators was that idursulfase-IT treatment was beneficial in some patients, having the potential to alter the course of MPS II disease, and with patients treated earlier (at a younger age or earlier in the disease process) experiencing the greatest benefit. The gene discussed is IDS; the disease is mucopolysaccharidosis type 2.